BioNTech (BNTX) announced that its subsidiary BioNTech UK Ltd. signed a grant agreement with the UK Government to broaden the company’s R&D activities for innovative medicines in the UK. As part of the agreement, BioNTech is committed to investing up to GBP 1B over the next 10 years. The company’s efforts will be supported by a grant of up to GBP 129M for a period of 10 years by the UK Government, which “marks one of the largest grants of its kind in UK history for a pharmaceutical company,” BioNTech stated. The grant is part of the UK Government’s mission to enhance its life sciences sector and support innovative companies with the aim to unlock progress in medical science, BioNTech added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- Promising Developments and Strategic Initiatives Drive Buy Rating for BioNTech SE
- BioNTech SE’s 2025 AGM Highlights Strategic Focus and Financial Strength
- CureVac granted favorable decision by European Patent Office vs. BioNTech
- HHS to drop recommendations for routine COVID shots for kids, WSJ reports
- FDA head says vaccine framework being prepared